Figure 1 4.1.1 Cardiovascular outcomes in SGLT2 inhibitors: safety studies The EMPA-REG OUTCOME trial, which included 7020 patients with T2DM, was the first to demonstrate the cardiovascular protective effects of empagliflozin (54, 56)
Temperature fluctuations, light exposure, and humidity accelerate this degradation, which is why licensed 503A compounding pharmacies assign expiration dates based on rigorous stability data
The starting dose is typically 0.25 mg once weekly for the first four weeks
Cannabis interacts with the endocannabinoid system, influencing mood, appetite, nausea, and sensory perception
The aging process, poor diet, and environmental toxins can stress the body's built-in antioxidant system, making it less capable of quenching free radicals
Traditionally, formulations such as Wegovy and Ozempic containing Semaglutide have been prescribed to treat Type 2 diabetics